Amphastar P (AMPH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Amphastar P stock (AMPH) is currently trading at $19.57. Amphastar P PE ratio is 9.61. Amphastar P PS ratio (Price-to-Sales) is 1.25. Analyst consensus price target for AMPH is $29.00. WallStSmart rates AMPH as Underperform.
- AMPH PE ratio analysis and historical PE chart
- AMPH PS ratio (Price-to-Sales) history and trend
- AMPH intrinsic value — DCF, Graham Number, EPV models
- AMPH stock price prediction 2025 2026 2027 2028 2029 2030
- AMPH fair value vs current price
- AMPH insider transactions and insider buying
- Is AMPH undervalued or overvalued?
- Amphastar P financial analysis — revenue, earnings, cash flow
- AMPH Piotroski F-Score and Altman Z-Score
- AMPH analyst price target and Smart Rating
Amphastar P
📊 No data available
Try selecting a different time range
AMPH Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Amphastar P (AMPH)
AMPH trades 107% above its Graham fair value of $13.80, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Amphastar P (AMPH) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, institutional own.. Concerns around revenue growth and eps growth. Fundamentals are solid but monitor weak areas for improvement.
Amphastar P (AMPH) Key Strengths (3)
76.66% of shares held by major funds and institutions
Paying $1.25 for every $1 of annual revenue
Trading at 1.12x book value, attractively priced
Supporting Valuation Data
Amphastar P (AMPH) Areas to Watch (7)
Revenue declining -1.80%, a shrinking business
Earnings declining -31.00%, profits shrinking
Paying a premium for growth, expensive relative to earnings expansion
Small-cap company with higher risk but more growth potential
Moderate profitability with room for improvement
Decent operational efficiency, solid but not exceptional
Decent profitability, keeps $14 per $100 revenue
Amphastar P (AMPH) Detailed Analysis Report
Overall Assessment
This company scores 52/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 3 register as strengths (avg 8.7/10) while 7 fall into concern territory (avg 3.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Sales, Price/Book. Valuation metrics including Price/Sales (1.25), Price/Book (1.12) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Revenue Growth, EPS Growth, PEG Ratio. Some valuation metrics including PEG Ratio (2.77) suggest expensive pricing. Growth concerns include Revenue Growth at -1.80%, EPS Growth at -31.00%, which may limit upside. Profitability pressure is visible in Return on Equity at 12.90%, Operating Margin at 19.50%, Profit Margin at 13.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 12.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -1.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Price/Sales) and negatives (Revenue Growth, EPS Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AMPH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AMPH's Price-to-Sales ratio of 1.25x trades at a deep discount to its historical average of 2.92x (1th percentile). The current valuation is 78% below its historical high of 5.7x set in Dec 2023, and 7% above its historical low of 1.16x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~1.8x as trailing revenue scaled faster than the stock price.
Compare AMPH with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Amphastar P (AMPH) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Amphastar P faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 720M with 2% decline year-over-year. Profit margins of 13.6% are healthy, with room for further expansion as the business scales.
Key Findings
Generating 25M in free cash flow and 33M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can Amphastar P push profit margins above 15% as the business scales?
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Amphastar P.
Bottom Line
Amphastar P faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Amphastar P(AMPH)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company is headquartered in Rancho Cucamonga, California.